• Publications
  • Influence
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
BACKGROUND In a previous meta-analysis, we identified a survival benefit from neoadjuvant chemotherapy or chemoradiotherapy before surgery in patients with resectable oesophageal carcinoma. WeExpand
  • 1,178
  • 45
  • Open Access
Lymphomas in E mu-Pim1 transgenic mice exposed to pulsed 900 MHZ electromagnetic fields.
Whether radiofrequency (RF) fields are carcinogenic is controversial; epidemiological data have been inconclusive and animal tests limited. The aim of the present study was to determine whetherExpand
  • 417
  • 34
Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial.
IMPORTANCE Laparoscopic procedures are generally thought to have better outcomes than open procedures. Because of anatomical constraints, laparoscopic rectal resection may not be better because ofExpand
  • 516
  • 31
  • Open Access
Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
BACKGROUND Resection remains the best treatment for carcinoma of the oesophagus in terms of local control, but local recurrence and distant metastasis remain an issue after surgery. We aimed toExpand
  • 812
  • 29
  • Open Access
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
BACKGROUND Resectable oesophageal cancer is often treated with surgery alone or with preoperative (neoadjuvant) chemoradiotherapy or chemotherapy. We aimed to clarify the benefits of neoadjuvantExpand
  • 1,026
  • 26
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3
BACKGROUND Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients with platinum-sensitive,Expand
  • 503
  • 24
  • Open Access
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer
BACKGROUND There are limited data from retrospective studies regarding whether survival outcomes after laparoscopic or robot‐assisted radical hysterectomy (minimally invasive surgery) are equivalentExpand
  • 361
  • 22
  • Open Access
Long-Term Exposure of Eμ-Pim1 Transgenic Mice to 898.4 MHz Microwaves does not Increase Lymphoma Incidence
Abstract Utteridge, T. D., Gebski, V., Finnie, J. W., Vernon-Roberts, B. and Kuchel, T. R. Long-Term Exposure of Eμ-Pim1 Transgenic Mice to 898.4 MHz Microwaves does not Increase Lymphoma Incidence.Expand
  • 133
  • 19
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
PURPOSE This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin (PLD) with carboplatin (CD)Expand
  • 424
  • 17
  • Open Access
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
PURPOSE To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC)Expand
  • 320
  • 15